Novel pharmacological targets for GABAergic dysfunction in ADHD.

Area of Science:

• Neuroscience
• Psychiatry
• Genetics

Background:

• Attention deficit/hyperactivity disorder (ADHD) affects ~5% of the population, characterized by impulsivity, hyperactivity, and attention deficits.
• Current stimulant treatments for ADHD target dopaminergic signaling but are ineffective for nearly one-third of patients and have unclear long-term side effects.
• Emerging evidence suggests dysregulated excitatory/inhibitory (E/I) balance, particularly involving GABAergic signaling, plays a crucial role in ADHD pathophysiology.

Purpose of the Study:

• To review the role of GABAergic dysfunction in ADHD pathophysiology.
• To explore potential pharmacological targets within GABAergic interneuron pathways for ADHD treatment.
• To discuss implications for subpopulations with specific comorbidities and symptom domains.

Main Methods:

• Review of current clinical evidence and emerging research on E/I balance in ADHD.
• Analysis of findings from genome-wide association studies (GWAS) linking GABA genes to ADHD.
• Examination of genetic mouse models of ADHD related to GABAergic dysfunction.

Main Results:

• Genetic studies and mouse models highlight mutations in GABA-related genes in ADHD populations.
• GABAergic interneuron dysfunction is increasingly recognized as a key mechanism in ADHD.
• Dysfunctional GABA signaling contributes to E/I imbalance observed in ADHD.

Conclusions:

• GABAergic dysfunction is a significant factor underlying ADHD pathophysiology.
• Targeting specific GABA receptors and proteins offers a promising therapeutic avenue for ADHD subpopulations.
• This approach may provide alternative treatments for patients unresponsive to stimulants or with specific comorbidities.